Form 4: Supernus Director Sells Shares Under 10b5-1 Plan

Supernus Pharmaceuticals Director Frederick M. Hudson sold 7,457 shares of common stock for a weighted average price of $42.26 per share.

Summary

• Frederick M. Hudson, a Director of Supernus Pharmaceuticals, Inc. (SUPN), reported a sale of common stock.
• The transaction involved the disposition of 7,457 shares of common stock.
• The shares were sold at a weighted average price of $42.26 per share, with prices ranging from $42.14 to $42.37.
• The sale was conducted on August 14, 2025, and reported on August 18, 2025.
• Following this transaction, Frederick M. Hudson beneficially owns 46,307 shares of Supernus common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) trading plan.

Sentiment

Score: 5

Explanation: The sale of shares by a director is typically viewed as a neutral to slightly negative signal; however, the transaction was executed under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not based on new, adverse material information, thus making the sentiment neutral.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a discretionary sale based on new, non-public information.

Negatives

• Insider selling, even under a pre-arranged plan, can sometimes be perceived by investors as a lack of confidence in the company's future prospects.

Risks

• No specific risks were detailed in this Form 4 filing beyond the inherent market risks associated with stock ownership and trading.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The filing was signed by Timothy C. Dec, as attorney-in-fact for Frederick M. Hudson.

Industry Context

This filing is a routine disclosure of an insider transaction, common across all publicly traded companies. It does not provide specific insights into broader pharmaceutical industry trends but reflects an individual director's pre-planned stock disposition.

Related Party Transactions

• Frederick M. Hudson, a Director of Supernus Pharmaceuticals, Inc., engaged in a sale of company common stock, which is considered a related-party transaction due to his insider status.

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a potential signal, though the Rule 10b5-1 plan mitigates concerns that the sale is based on new, negative information.

Key Dates

Recommendation

A single Form 4 filing detailing a pre-planned insider sale, while noteworthy, typically does not warrant a strong buy or sell recommendation. The Rule 10b5-1 plan suggests the sale is for personal financial planning rather than a reflection of new company-specific negative developments, leading to a neutral 'hold' stance.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, insider trading, stock sale, director, common stock, Rule 10b5-1